Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study

BACKGROUND: The immunotherapy plus chemotherapy combination is one of the most promising treatments in advanced non-small-cell lung cancer (NSCLC). Immunotherapy often causes immune-related adverse events (irAEs), which have been reported to be associated with the good clinical outcomes. However, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Morimoto, Kenji, Yamada, Tadaaki, Takumi, Chieko, Ogura, Yuri, Takeda, Takayuki, Onoi, Keisuke, Chihara, Yusuke, Taniguchi, Ryusuke, Yamada, Takahiro, Hiranuma, Osamu, Morimoto, Yoshie, Iwasaku, Masahiro, Kaneko, Yoshiko, Uchino, Junji, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021904/
https://www.ncbi.nlm.nih.gov/pubmed/33833990
http://dx.doi.org/10.3389/fonc.2021.630136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021904/
https://www.ncbi.nlm.nih.gov/pubmed/33833990
http://dx.doi.org/10.3389/fonc.2021.630136

Ejemplares similares